Predicting psoriasis response using advanced skin-cell testing
Treatments studied
Part of Skin clinical trials.
This study looks at skin cells at the single-cell level to predict which psoriasis treatments will work best for you. It may help doctors personalize treatment choices for plaque psoriasis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have plaque-type psoriasis confirmed by a dermatologist or skin biopsy
- You must not have taken ustekinumab (Stelara), guselkumab (Tremfya), or risankizumab (Skyrizi) before
- Your insurance must cover Stelara plus at least one of Tremfya or Skyrizi
- At screening and the start of the study, at least 10% of your body surface area must be covered by psoriasis
- You must be able and willing to sign consent to join the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study uses a special camera to track how ustekinumab (a common biologic medicine) spreads in inflamed tissue. It aims to help researchers understand where the drug goes in Crohn’s disease and psoriasis, especially when standard treatments haven’t worked.
This study looks at what’s happening inside the body in people with plaque psoriasis who start certain biologic medicines that target the IL-23/IL-17 immune pathway. It may help explain why these treatments work and what body changes are linked to response.
This study follows people starting a new advanced psoriasis treatment to see how well it works over 16 weeks. You'll have three office visits with your dermatologist, and researchers will track your skin improvement to help understand which treatments work best for different patients.
This study looks at the immune cells in skin samples from people with psoriasis who are being treated with an anti-IL-23 biologic. The goal is to understand why some areas of skin do not improve or why flares happen, which may help improve treatments.
This study is testing how well a topical betamethasone (a steroid cream) works for psoriasis. It is designed for people who have psoriasis on their skin and can use a smartphone app to track their progress.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.